Novaliq GmbH is using semifluorinated alkanes to improve solubility of topical agents like cyclosporin and latanoprost on the ocular surface, according to CEO Bernhard Günther. CyclASol and TacroSol compounds, which are ready for Phase II studies, pair with cyclosporine for dry eye and tacrolimus for uveitis, respectively, said Günther. Novaliq also has in development other formulations for post-cataract pain and mild and moderate dry eye. Its OTC platform for dry eye, NovaTears, received the CE Mark in 2014, and Günther expects the company to receive the CE Mark designation for NovaTears Omega3 in 2015.
Bernhard Günther joined Novaliq as CEO in January 2007. He has more than 20 years of experience in the field of ocular biopharmaceutics and medical devices.